Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

E von der Heyde; D Burkle; H Forstbauer; G Hubner; B Schmidt; J Schroder; A Distelrath; J Wierecky; P Stubs; J Kisro; M Welslau; H Muller-Huesmann; T Gohler; B Krammer-Steiner; I Schwaner; C Hering-Schubert; Armin Gerger; R Greil; L Jacobasch; F Reichenbach; S Stintzing; G Prager

doi:10.1016/j.annonc.2022.04.099

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

E von der Heyde
, D Burkle
, H Forstbauer
, G Hubner
, B Schmidt
, J Schroder
, A Distelrath
, J Wierecky
, P Stubs
, J Kisro
, M Welslau
, H Muller-Huesmann
, T Gohler
, B Krammer-Steiner
, I Schwaner
, C Hering-Schubert
, Armin Gerger
, R Greil
, L Jacobasch
, F Reichenbach

S Stintzing, G Prager

Division of Oncology

Research output: Contribution to journal › Conference abstract

Original language	English
Journal	Annals of Oncology
DOIs	https://doi.org/10.1016/j.annonc.2022.04.099
Publication status	Published - 2022
Event	European Society for Medical Oncology Breast Cancer Congress 2022 - Berlin, Germany Duration: 3 May 2022 → 5 May 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Branches of science

302 Clinical Medicine

DOI

10.1016/j.annonc.2022.04.099

Links

Web of Science

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC
von der Heyde, E. (Author), Burkle, D. (Author), Forstbauer, H. (Author), Hubner, G. (Author), Schmidt, B. (Author), Schroder, J. (Author), Distelrath, A. (Author), Wierecky, J. (Author), Stubs, P. (Author), Kisro, J. (Author), Welslau, M. (Author), Muller-Huesmann, H. (Author), Gohler, T. (Author), Krammer-Steiner, B. (Author), Schwaner, I. (Author), Hering-Schubert, C. (Author), Gerger, A. (Author), Greil, R. (Author), Jacobasch, L. (Author), Reichenbach, F. (Author), Stintzing, S. (Author) & Prager, G. (Author)
2022
Activity: Talk, presentation or poster › Poster

Cite this

von der Heyde, E., Burkle, D., Forstbauer, H., Hubner, G., Schmidt, B., Schroder, J., Distelrath, A., Wierecky, J., Stubs, P., Kisro, J., Welslau, M., Muller-Huesmann, H., Gohler, T., Krammer-Steiner, B., Schwaner, I., Hering-Schubert, C., Gerger, A., Greil, R., Jacobasch, L., ... Prager, G. (2022). Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC. Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.04.099

@article{2e2beb0cbf644027bd6139742e9971a1,

title = "Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC",

author = "\{von der Heyde\}, E and D Burkle and H Forstbauer and G Hubner and B Schmidt and J Schroder and A Distelrath and J Wierecky and P Stubs and J Kisro and M Welslau and H Muller-Huesmann and T Gohler and B Krammer-Steiner and I Schwaner and C Hering-Schubert and Armin Gerger and R Greil and L Jacobasch and F Reichenbach and S Stintzing and G Prager",

year = "2022",

doi = "10.1016/j.annonc.2022.04.099",

language = "English",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd",

note = "European Society for Medical Oncology Breast Cancer Congress 2022, ESMO BC 2022 ; Conference date: 03-05-2022 Through 05-05-2022",

}

von der Heyde, E, Burkle, D, Forstbauer, H, Hubner, G, Schmidt, B, Schroder, J, Distelrath, A, Wierecky, J, Stubs, P, Kisro, J, Welslau, M, Muller-Huesmann, H, Gohler, T, Krammer-Steiner, B, Schwaner, I, Hering-Schubert, C, Gerger, A, Greil, R, Jacobasch, L, Reichenbach, F, Stintzing, S & Prager, G 2022, 'Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC', Annals of Oncology. https://doi.org/10.1016/j.annonc.2022.04.099

TY - JOUR

T1 - Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

AU - von der Heyde, E

AU - Burkle, D

AU - Forstbauer, H

AU - Hubner, G

AU - Schmidt, B

AU - Schroder, J

AU - Distelrath, A

AU - Wierecky, J

AU - Stubs, P

AU - Kisro, J

AU - Welslau, M

AU - Muller-Huesmann, H

AU - Gohler, T

AU - Krammer-Steiner, B

AU - Schwaner, I

AU - Hering-Schubert, C

AU - Gerger, Armin

AU - Greil, R

AU - Jacobasch, L

AU - Reichenbach, F

AU - Stintzing, S

AU - Prager, G

PY - 2022

Y1 - 2022

UR - https://www.webofscience.com/wos/woscc/full-record/WOS:000823826500022

U2 - 10.1016/j.annonc.2022.04.099

DO - 10.1016/j.annonc.2022.04.099

M3 - Conference abstract

SN - 0923-7534

JO - Annals of Oncology

JF - Annals of Oncology

T2 - European Society for Medical Oncology Breast Cancer Congress 2022

Y2 - 3 May 2022 through 5 May 2022

ER -

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

UN SDGs

Branches of science

DOI

Links

Activities

Encorafenib and cetuximab in patients with metastatic, BRAF V600E-mutated, colorectal cancer: Update on the first real-world study in Germany and Austria BERING CRC

Cite this